A Phase I, Open-Label, Dose-Escalating Study Of The Safety, Tolerability, And Anti-Tumor Activity Of A Single Intrahepatic Arterial Injection Of Genetically Engineered Herpes Simplex Virus, NV1020, In Subjects With Adenocarcinoma Of The Colon With Metastasis To The Liver
Phase of Trial: Phase I
Latest Information Update: 25 Jun 2013
At a glance
- Drugs NV 1020 (Primary)
- Indications Colon cancer; Liver cancer
- Focus Adverse reactions
- 17 Dec 2009 Actual end date (Nov 2002) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Sep 2005 New trial record.